Cargando…

Clinical Features and Therapeutic Effects of Anti-leucine-rich Glioma Inactivated 1 Encephalitis: A Systematic Review

Background: Clinical presentations and treatment programs about anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis still remain incompletely understood. Objective: This study analyzed the clinical features and therapeutic effects of anti-LGI1 encephalitis. Methods: PubMed, EMBASE, and the Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, Yuou, Li, Ting, Yang, Zhizhong, Su, Mingwan, Ni, Jingnian, Wei, Mingqing, Shi, Jing, Tian, Jinzhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791026/ https://www.ncbi.nlm.nih.gov/pubmed/35095736 http://dx.doi.org/10.3389/fneur.2021.791014

Ejemplares similares

Motor Phenomena Associated With Leucine-Rich Glioma-Inactivated (LGI1) Emi-Encephalitis
por: Giorelli, Maurizio, et al.
Publicado: (2023)

Clinical Features and Gut Microbial Alterations in Anti-leucine-rich Glioma-Inactivated 1 Encephalitis—A Pilot Study
por: Ma, Xueying, et al.
Publicado: (2020)

Effect of hearing aids on cognitive functions in middle-aged and older adults with hearing loss: A systematic review and meta-analysis
por: Yang, Zhizhong, et al.
Publicado: (2022)

The First Case of Familiar Anti-leucine-rich Glioma-Inactivated1 Autoimmune Encephalitis: A Case Report and Literature Review
por: Ding, Chuhan, et al.
Publicado: (2022)

Arterial Spin Labeling Imaging Characteristics of Anti-leucine-rich Glioma-Inactivated 1 Encephalitis: A Qualitative and Quantitative Analysis
por: Yedavalli, Vivek Srikar, et al.
Publicado: (2022)

Cortical metabolic characteristics of anti-leucine-rich glioma-inactivated 1 antibody encephalitis based on (18)F-FDG PET
por: Wang, Kai, et al.
Publicado: (2023)

Leucine-Rich Glioma-Inactivated 1 Encephalitis: Broadening the Sphere
por: Rachdi, Amine, et al.
Publicado: (2019)

Brain Magnetic Resonance Imaging Characteristics of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis and Their Clinical Relevance: A Single-Center Study in China
por: Shao, Xiali, et al.
Publicado: (2021)

Anti-Leucine-Rich Glioma-Inactivated 1 (Anti-LGI 1) Limbic Encephalitis and New-Onset Psychosis: A Case Report
por: Alho, António, et al.
Publicado: (2023)

Systematic review: clinical characteristics of anti-N-methyl-D-aspartate receptor encephalitis
por: Zhao, Xi, et al.
Publicado: (2023)

An Unusual Case of LGI1 (Leucine-Rich Glioma-Inactivated Protein 1) Limbic Encephalitis With Anti-acetylcholine Receptor and Anti-striational Autoantibodies
por: Pathak, Akash, et al.
Publicado: (2023)

Limbic encephalitis associated with leucine-rich glioma-inactivated 1 antibodies
por: Messelmani, Mariem, et al.
Publicado: (2015)

A Case of Anti-Leucine-Rich Glioma-Inactivated Protein 1 (Anti-LGI1) Encephalitis With an Unusual Frontomesial Motor Cortex T2 MRI Hyperintensity
por: Papiri, Giulio, et al.
Publicado: (2022)

Anti-leucine-rich Glioma Inactivated-1 Encephalitis Associated with Essential Thrombocythemia
por: Yuan, Xiaoling, et al.
Publicado: (2020)

Leucine-rich glioma-inactivated protein 1 antibody encephalitis: A case report
por: Mayasi, Yunis, et al.
Publicado: (2014)

Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases
por: Lin, Nan, et al.
Publicado: (2020)

CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
por: Lin, You-ting, et al.
Publicado: (2019)

Leucine-rich Glioma-inactivated 1 Encephalitis Followed by Isaacs Syndrome: Alternating Presence of Pathogenic Autoantibodies to Leucine-rich Glioma-inactivated 1 and Contactin-associated Protein-like 2
por: Murayama, Aki, et al.
Publicado: (2022)

Corrigendum: Sleep Disorders in Leucine-Rich Glioma-Inactivated Protein 1 and Contactin Protein-Like 2 Antibody-Associated Diseases
por: Lin, Nan, et al.
Publicado: (2020)

Reversible Bilateral Striatal Hypermetabolism in a Patient with Leucine-Rich Glioma Inactivated-1 Encephalitis
por: Takkar, Aastha, et al.
Publicado: (2016)

Clinical Features and Long-Term Outcomes of Anti-Leucine-Rich Glioma-Inactivated 1 Encephalitis: A Multi-Center Study
por: Qiao, Shan, et al.
Publicado: (2021)

Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis
por: Binks, Sophie N. M., et al.
Publicado: (2021)

Anti-leucine-rich glioma-inactivated 1 encephalitis: two case reports and a review of the literature
por: Karvigh, Sanaz Ahmadi, et al.
Publicado: (2022)

Clinical analysis of leucine-rich glioma inactivated-1 protein antibody associated with limbic encephalitis onset with seizures
por: Li, Zhimei, et al.
Publicado: (2016)

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Letter]
por: Wei, Mingyu, et al.
Publicado: (2020)

Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis
por: Sola-Valls, Nuria, et al.
Publicado: (2019)

Persistent hiccup as one of the initial symptoms of leucine-rich glioma-inactivated-1 encephalitis: a case report
por: Hou, Lan, et al.
Publicado: (2022)

Leucine-Rich Glioma-Inactivated Protein 1 Antibody-Positive Polyradiculopathy Associated with Epstein-Barr Virus Infection
por: Uzunalimoğlu, Berrin Pelit, et al.
Publicado: (2021)

Anti-leucine-rich Glioma-inactivated-1 Encephalitis with Faciobrachial Dystonic Seizures and Behavioral Problems: A Case Report
por: Adhikari, Ayush, et al.
Publicado: (2020)

CXCL13 Is a Biomarker of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients [Response to Letter]
por: Wang, Sheng-jun, et al.
Publicado: (2020)

Serial assessment of multimodality imaging in anti-leucine-rich glioma-inactivated 1 antibody encephalitis: A case report
por: Wada, Takafumi, et al.
Publicado: (2022)

CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis
por: Li, Jinyi, et al.
Publicado: (2023)

A case of leucine-rich glioma-inactivated 1 antibody encephalitis with schizophrenia-like symptoms as an initial clinical manifestation
por: Moon, Jiyeon, et al.
Publicado: (2022)

A Psychiatric Side Effect of Levetiracetam Can Mimic a Relapse of Anti-Leucine-Rich Glioma Inactivated 1 Encephalitis
por: Jang, Yoonhyuk, et al.
Publicado: (2018)

COVID-19-Vaccine-Pfizer-BioNTech: Anti-leucine rich glioma inactivated 1 autoimmune encephalitis: case report
Publicado: (2022)

Abnormal DNA methylation analysis of leucine-rich glioma-inactivated 1 antibody encephalitis reveals novel methylation-driven genes related to prognostic and clinical features
por: Qiao, Shan, et al.
Publicado: (2023)

Discrimination between leucine-rich glioma-inactivated 1 antibody encephalitis and gamma-aminobutyric acid B receptor antibody encephalitis based on ResNet18
por: Pan, Jian, et al.
Publicado: (2023)

Leucine-rich glioma inactivated 3: integrative analyses support its prognostic role in glioma
por: Kwon, Nyoun Soo, et al.
Publicado: (2017)

Leucine-Rich Glioma Inactivated-1 and Voltage-Gated Potassium Channel Autoimmune Encephalitis Associated with Ischemic Stroke: A Case Report
por: McGinley, Marisa, et al.
Publicado: (2016)

Leucine-Rich Glioma-Inactivated Protein 1 Antibody-Positive Limbic Encephalitis in a Patient with Adenocarcinoma of Prostate: A Case Report
por: Navalli, Devaraddi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_un4jpbvtqtrco5sakf0lj2c3nj